Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
41
MRK Quote, Financials, Valuation and Earnings
Last price:
$83.57
Seasonality move
:
2.23%
Day range:
$78.06 - $83.28
52-week range:
$75.93 - $134.63
Dividend yield:
3.82%
P/E ratio:
12.04x
P/S ratio:
3.28x
P/B ratio:
4.50x
Volume:
27.7M
Avg. volume:
18.1M
1-year change:
-36.7%
Market cap:
$208.2B
Revenue:
$64.2B
EPS (TTM):
$6.87
Analysts' Opinion
-
Consensus RatingMerck & has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 11 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $108.19, Merck & has an estimated upside of 30.76% from its current price of $82.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $82.00 representing 0.89% downside risk from its current price of $82.74.
Fair Value
-
According to the consensus of 22 analysts, Merck & has 30.76% upside to fair value with a price target of $108.19 per share.
MRK vs. S&P 500
-
Over the past 5 trading days, Merck & has overperformed the S&P 500 by 1.42% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Merck & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Merck & revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Merck & reported revenues of $15.5B.
Earnings Growth
-
Merck & has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Merck & reported earnings per share of $2.01.
Enterprise value:
231.7B
EV / Invested capital:
--
Price / LTM sales:
3.28x
EV / EBIT:
10.94x
EV / Revenue:
3.62x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
12.80x
Price / Operating cash flow:
11.21x
Enterprise value / EBITDA:
9.39x
Gross Profit (TTM):
$48.9B
Return On Assets:
15.39%
Net Income Margin (TTM):
27.27%
Return On Equity:
40.25%
Return On Invested Capital:
21.64%
Operating Margin:
38.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $57.9B | $61.4B | $63.9B | $15.8B | $15.5B | |
| Gross Profit | $41.9B | $45.7B | $48.9B | $12.2B | $12.1B | |
| Operating Income | $16.5B | $4.9B | $20.4B | $5.8B | $5.9B | |
| EBITDA | $20B | $9B | $24.7B | $7B | $5.9B | |
| Diluted EPS | $5.12 | $0.90 | $6.87 | $1.87 | $2.01 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.9B | $31.2B | $33.4B | $31.4B | -- | |
| Total Assets | $90.8B | $106.7B | $107.8B | $105.8B | -- | |
| Current Liabilities | $26.4B | $22.3B | $23.1B | $25.1B | -- | |
| Total Liabilities | $63.8B | $65.7B | $60.9B | $65.4B | -- | |
| Total Equity | $27B | $41B | $46.9B | $40.4B | -- | |
| Total Debt | $31.3B | $31.8B | $30.7B | $34.2B | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $19.1B | $13B | $21.5B | $246M | $3.5B | |
| Cash From Investing | -$5B | -$14.1B | -$7.7B | $53M | -$1.4B | |
| Cash From Financing | -$9.1B | -$4.8B | -$7B | -$2.2B | -$3B | |
| Free Cash Flow | $14.7B | $9.1B | $18.1B | -$743M | $2.5B | |
MRK
Sector
Market Cap
$208.2B
$35M
Price % of 52-Week High
61.46%
44.47%
Dividend Yield
3.82%
0%
Shareholder Yield
7.2%
-0.9%
1-Year Price Total Return
-36.7%
-38.53%
Beta (5-Year)
0.401
0.738
Dividend yield:
3.82%
Annualized payout:
$3.12
Payout ratio:
33.79%
Growth streak:
14 years
Technicals
8-day SMA
Buy
Level
$78.87
200-day SMA
Sell
Level
$102.88
Bollinger Bands (100)
Sell
Level
85.15 - 100.51
Chaikin Money Flow
Buy
Level
721.4M
20-day SMA
Buy
Level
$81.48
Relative Strength Index (RSI14)
Sell
Level
49.07
ADX Line
Sell
Level
33.7
Williams %R
Sell
Level
-7.3469
50-day SMA
Sell
Level
$87.02
MACD (12, 26)
Sell
Level
-2.62
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
619.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1386)
Buy
CA Score
(Annual)
Level (0.0398)
Buy
Beneish M-Score
(Annual)
Level (-2.6876)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.2238)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Stock Forecast FAQ
In the current month, MRK has received 11 Buy ratings 11 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $108.19.
-
Where Will Merck & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Merck & share price will rise to $108.19 per share over the next 12 months.
-
What Do Analysts Say About Merck &?
Analysts are divided on their view about Merck & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Merck & is a Sell and believe this share price will drop from its current level to $82.00.
-
What Is Merck &'s Price Target?
The price target for Merck & over the next 1-year time period is forecast to be $108.19 according to 22 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is MRK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Merck & is a Leans Bullish. 11 of 22 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of MRK?
You can purchase shares of Merck & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Merck & shares.
-
What Is The Merck & Share Price Today?
Merck & was last trading at $83.57 per share. This represents the most recent stock quote for Merck &. Yesterday, Merck & closed at $82.74 per share.
-
How To Buy Merck & Stock Online?
In order to purchase Merck & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 28
Saia [SAIA] is down 3.72% over the past day.
Sell
48
APPF alert for Apr 28
AppFolio [APPF] is up 0.76% over the past day.
Sell
15
KNSL alert for Apr 28
Kinsale Capital Group [KNSL] is up 1.66% over the past day.
